

# MEDICAL POLICY

MEDICAL POLICY DETAILS	
Medical Policy Title	Immunizations
Policy Number	2.01.42
Category	Technology Assessment
Original Effective Date	09/16/04
Committee Approval Date	10/20/05, 09/21/06, 07/19/07, 08/21/08, 07/16/09, 07/15/10, 07/21/11, 07/19/12, 07/18/13, 07/17/14, 07/16/15, 07/21/16, 07/20/17, 05/17/18, 05/16/19, 05/21/20, 09/17/20, 12/17/20, 03/18/21, 05/20/21, 12/16/21, 05/19/22, 12/22/22, 05/18/23
Current Effective Date	05/18/23
Archived Date	N/A
Archive Review Date	N/A
Product Disclaimer	<ul style="list-style-type: none"> <li>• If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.</li> <li>• If a commercial product (including an Essential Plan or Child Health Plus product), medical policy criteria apply to the benefit.</li> <li>• If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit.</li> <li>• If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.</li> <li>• If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.</li> </ul>

## POLICY STATEMENT

Childhood and adult immunizations are considered **medically appropriate** when administered according to the schedule of adult or child and adolescent immunizations and official recommendations of the Advisory Committee on Immunization Practices (ACIP) to the Centers for Disease Control and Prevention (CDC).

## POLICY GUIDELINES

- I. Vaccines related to or required only as a condition of work, travel, or school are **ineligible for coverage**, unless specifically covered under the member's subscriber contract or otherwise required by law.
- II. ACIP recommendations are effective as of the date on which the Morbidity and Mortality Weekly Report (MMWR) is publicized by the CDC.
- III. Coverage criteria are adjusted when national guidelines are revised to address new vaccines or changes in vaccine indications, or when the CDC makes recommendations for changes in administration schedules related to national vaccine shortages.

## DESCRIPTION

Immunization is the process of stimulating the body's immune system to protect against a specific infection. Minute amounts of the specific bacteria or virus, in whole or part, are specially treated so that, when given to the patient, they will stimulate the body's immune system without actually causing disease. Some immunizations require "boosters," or repeat doses of the same vaccine, to keep up the body's protection against a specific bacteria or virus.

Recommended pediatric and adult immunizations are addressed as part of the Health Plan's Preventive Health Guidelines.

**Medical Policy: IMMUNIZATIONS****Policy Number: 2.01.42****Page: 2 of 10**

ACIP’s “Recommended Child and Adolescent Immunization Schedule – For Ages 18 years and Younger,” and the “Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 Month Behind,” have been approved by the CDC, as well as by the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG), and the American College of Nurse-Midwives. The schedules can be referenced at:

<https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf>

**The following immunizations are included in the recommendations for children and adolescents aged 18 years or younger, based on medical indications:**

Dengue	Influenza (Seasonal) (IIV4 or LAIV4)	Poliovirus Inactivated (IPV)
Diphtheria-Tetanus- acellular Pertussis (DTaP), Diphtheria-Tetanus (DT)	Measles, Mumps, Rubella (MMR)	Rotavirus (RV1 or RV5)
Haemophilus influenzae type b (Hib)	Meningococcal serogroups A, C, W, Y (MenACWY-D, MenACWY-CRM, MenACWY-TT)	Tetanus-diphtheria and acellular pertussis (Tdap)
Hepatitis A (Hep A)	Meningococcal serogroup B (MenB-4C or MenB-FHbp)	Tetanus-diphtheria (Td)
Hepatitis B (Hep B)	Pneumococcal conjugate (PCV13, PCV 15, PCV20)	Varicella (VAR)
Human Papillomavirus (HPV)	Pneumococcal polysaccharide (PPSV23)	

**The following combination vaccines are used instead of separate injections, when appropriate:**

DTaP, hepatitis B, and inactivated poliovirus (DTaP-HepB-IPV)	DTaP and inactivated poliovirus (DTaP-IPV)	Measles, mumps, rubella, and varicella (MMRV)
DTaP, inactivated poliovirus, and Haemophilus influenzae type b (DTaP-IPV/Hib)	DTaP, inactivated poliovirus, Haemophilus influenzae type b and hepatitis B (DTaP-IPV-Hib-HepB)	

ACIP’s “Recommended Adult Immunization Schedule for Ages 19 Years and Older” guidelines include immunization schedules and information for both persons at “usual risk” and “at risk.” These guidelines are based primarily on recommendations from the Report of the U.S. Preventive Services Task Force and the Department of Health and the CDC’s “Recommended Adult Immunization Schedule for Ages 19 Years and Older,” which can be referenced at:

<https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html>

**The following immunizations for adults aged 19 years or older are included in the recommendations:**

Haemophilus influenzae type b (Hib)	Human Papillomavirus (HPV)	Meningococcal serogroup B (MenB-4C or MenB-F-Hbp)	Tetanus-diphtheria (Td)
Hepatitis A (Hep A)	Influenza (Seasonal) (IIV4, LAIV4 or RIV4)	Pneumococcal conjugate (PCV15, PCV20)	Tetanus-diphtheria and acellular pertussis (Tdap)

**Medical Policy: IMMUNIZATIONS****Policy Number: 2.01.42****Page: 3 of 10**

Hepatitis A and hepatitis B (HepA-HepB)	Measles, Mumps, Rubella (MMR)	Pneumococcal polysaccharide (PPSV23)	Varicella (VAR)
Hepatitis B (Hep B)	Meningococcal serogroup B (MenB-4C or MenB-F-Hbp)	Poliovirus (IPV)	Zoster Recombinant (RZV)

The New York Insurance Law requires that every health insurance policy providing medical, major medical, or similar comprehensive-type coverage provide benefits for necessary immunizations, as recommended by the ACIP to the CDC.

**CODES**

- *Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.*
- *CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.*
- *Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.*
- *Code Key: Experimental/Investigational = (E/I), Not medically necessary/appropriate = (NMN).*

**CPT Codes**

<b>Code</b>	<b>Description</b>
90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use (Neonates and infants up to 24 months old) (Report 96380 or 96381 for the administration of respiratory syncytial virus, monoclonal antibody, seasonal dose [90380, 90381])
90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use (Neonates and infants up to 24 months old) (Report 96380 or 96381 for the administration of respiratory syncytial virus, monoclonal antibody, seasonal dose [90380, 90381])
90460	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered
90461	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)
90472	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)
90473	Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid)
90474	Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)
90581	Anthrax vaccine, for subcutaneous or intramuscular use
90584 (E/I)	Dengue vaccine, quadrivalent, live, 2 dose schedule, for subcutaneous
90587	Dengue vaccine, quadrivalent, live, 3 dose schedule, for subcutaneous use
90611	Smallpox and monkeypox vaccine, attenuated vaccine virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use

**Medical Policy: IMMUNIZATIONS****Policy Number: 2.01.42****Page: 4 of 10**

<b>Code</b>	<b>Description</b>
90619	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use
90620	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use
90621	Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use
90622	Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use
90626	Tick-borne encephalitis virus vaccine, inactivated; 0.25 mL dosage, for intramuscular use
90627	Tick-borne encephalitis virus vaccine, inactivated; 0.5 mL dosage, for intramuscular use
90630	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use
90632	Hepatitis A vaccine (HepA), adult dosage, for intramuscular use
90633	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use
90634	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-3 dose schedule, for intramuscular use
90636	Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use
90644	Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type b vaccine (Hib-MenCY), 4 dose schedule, when administered to children 6 weeks-18 months of age, for intramuscular use
90647	Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use
90648	Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use
90649	Human Papillomavirus vaccine, types 6, 11, 16, 18, quadrivalent (4vHPV), 3 dose schedule, for intramuscular use
90650	Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use
90651	Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use
90653	Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use
90654	Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use
90655	Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use
90656	Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use
90657	Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use
90658	Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use
90660	Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use
90661	Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use

**Medical Policy: IMMUNIZATIONS****Policy Number: 2.01.42****Page: 5 of 10**

<b>Code</b>	<b>Description</b>
90662	Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use
90664	Influenza virus vaccine, live (LAIV), pandemic formulation, for intranasal use
90666 (E/I)	Influenza virus vaccine (IIV), pandemic formulation, split virus, preservative free, for intramuscular use
90667 (E/I)	Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use
90668 (E/I)	Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use
90670	Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use
90671	Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use (Effective Date 07/01/2021)
90672	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use
90673	Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
90674	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use
90677	Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use
90678	Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use
90679	Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use
90680	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use
90681	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use
90682	Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
90685	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL, for intramuscular use
90686	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
90687	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use
90688	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use
90689	Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25 mL dosage, for intramuscular use
90694	Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use
90696	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use
90697	Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use
90698	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use

**Medical Policy: IMMUNIZATIONS****Policy Number: 2.01.42****Page: 6 of 10**

<b>Code</b>	<b>Description</b>
90700	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use
90702	Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use
90707	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use
90710	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use
90713	Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use
90714	Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use
90715	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use
90716	Varicella virus vaccine (VAR), live, for subcutaneous use
90723	Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use
90732	Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use
90733	Meningococcal polysaccharide vaccine, serogroups A, C, Y, W-135, quadrivalent (MPSV4), for subcutaneous use
90734	Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use
90736	Zoster (shingles) vaccine (HZV), live, for subcutaneous injection
90739	Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule, for intramuscular use
90740	Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use
90743	Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use
90744	Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use
90746	Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use
90747	Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use
90748	Hepatitis B and Haemophilus influenzae type b vaccine (Hib-HepB), for intramuscular use
90750	Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use
90756	Influenza virus vaccine, quadrivalent (ccIV4), derived from cell cultures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use
90758	Zaire ebolavirus vaccine, live, for intramuscular use
90759	Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use

*Copyright © 2023 American Medical Association, Chicago, IL***COVID-19 Vaccine and Administration Codes**

As of April 18, 2023 the following monovalent Moderna and Pfizer-BioNTech COVID-19 vaccine and administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0051A, 0052A, 0053A, 0054A,

**Medical Policy: IMMUNIZATIONS****Policy Number: 2.01.42****Page: 7 of 10**

0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A 91300, 91301, 91305, 91306, 91307, 91308, 91309, 91311) are no longer FDA authorized for use in the United States.

<b>Code</b>	<b>Description</b>
90480	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose (Report 90480 for the administration of vaccine 91304, 91318, 91319, 91320, 91321, 91322)
91304	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5mL dosage, for intramuscular use (Novavax) (Report 91304 with administration code 90480)
91318	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (Report 91318 with administration code 90480) (Pfizer 6 months- 4 years)
91319	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use (Report 91319 with administration code 90480) (Pfizer 5 years – 11 years)
91320	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Report 91320 with administration code 90480) (Pfizer 12 years and older)
91321	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use (Report 91321 with administration code 90480) (Moderna 6 months – 11 years)
91322	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use (Report 91321 with administration code 90480) (Moderna 12 years and older)

**HCPCS Codes**

<b>Code</b>	<b>Description</b>
G0008	Administration of influenza virus vaccine
G0009	Administration of pneumococcal vaccine
G0010	Administration of hepatitis B vaccine
Q2034	Influenza virus vaccine, split virus, for intramuscular use (Agriflu)
Q2035	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (AFLURIA)
Q2036	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLULAVAL)
Q2037	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLUVIRIN)
Q2038	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluzone)
Q2039	Influenza virus vaccine, not otherwise specified

## Medical Policy: IMMUNIZATIONS

Policy Number: 2.01.42

Page: 8 of 10

### ICD10 Codes

Code	Description
Z23	Encounter for immunization

### REFERENCES

\*Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC) [<https://www.cdc.gov/vaccines/acip/index.html>] accessed 04/21/23.

American Academy of Pediatrics. Immunization. 2022 Feb [<https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/immunizations/Pages/Immunizations-home.aspx?>] accessed 04/21/23.

American College of Obstetricians and Gynecologists. Committee on Adolescent Health; Immunization Expert Work Group of the American College of Obstetricians and Gynecologists. Committee opinion no. 809: human papillomavirus vaccination. *Obstet Gynecol* 2020 Aug [<https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/08/human-papillomavirus-vaccination>] accessed 04/21/23.

American College of Obstetricians and Gynecologists. Committee on Obstetric Practice. Committee Opinion No. 732: Influenza vaccination during pregnancy. 2018 Apr [<https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2018/04/influenza-vaccination-during-pregnancy>] accessed 04/21/2023.

American College of Obstetricians and Gynecologists. Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. Committee Opinion No. 741: Maternal immunization. 2021 Oct [<https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2018/06/maternal-immunization>] accessed 04/21/2023.

American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 718: Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Reaffirmed 2022 [<https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/09/update-on-immunization-and-pregnancy-tetanus-diphtheria-and-pertussis-vaccination>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Immunization Schedules. Last updated 2022 Feb. [<https://www.cdc.gov/vaccines/schedules/index.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Anthrax** ACIP Vaccine Recommendations. Last updated 2020 Jan [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/anthrax.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Covid-19** ACIP Vaccine Recommendations. Last updated 2022 Jul [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Dengue** ACIP Vaccine Recommendations. Last updated 2021 Dec. [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/dengue.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **DTaP** ACIP Vaccine Recommendations. Last updated 2020 Jan [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/dtap.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Hepatitis A** ACIP Vaccine Recommendations. Last updated 2020 Jul [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepa.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Hepatitis B** ACIP Vaccine Recommendations. Last updated 2022 Apr [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html>] accessed 04/21/2023.



## Medical Policy: IMMUNIZATIONS

Policy Number: 2.01.42

Page: 9 of 10

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Hib** ACIP Vaccine Recommendations (Haemophilus Influenzae type B). Last updated 2016 Apr [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Human Papillomavirus (HPV)** ACIP Vaccine Recommendations. Last updated 2019 Aug [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Influenza** ACIP Vaccine Recommendations. Last updated 2022 Aug [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Japanese Encephalitis** ACIP Vaccine Recommendations. Last updated 2019 Jul [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/je.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). MMR ACIP Vaccine Recommendations (**Measles, Mumps and Rubella**). Last updated 2018 Jan [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmr.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). MMRV ACIP Vaccine Recommendations (**Measles, Mumps, Rubella, and Varicella**). Last reviewed 2014 Nov [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmr.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Meningococcal** ACIP Vaccine Recommendations. Last updated 2020 Sep [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Pneumococcal** ACIP Vaccine Recommendations. Last updated 2022 Sep [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Polio** ACIP Vaccine Recommendations. Last updated 2022 May [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/polio.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Respiratory Syncytial Virus (RSV) VIS** ACIP Vaccine Recommendations. Current Edition 07/24/2023 [<https://www.cdc.gov/vaccines/hcp/vis/vis-statements/rsv.html>] accessed 08/04/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Rotavirus** ACIP Vaccine Recommendations. Last reviewed 2014 Nov [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/rotavirus.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Orthopoxviruses (Smallpox and Monkeypox)** ACIP Vaccine Recommendations. 2022 Jun [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/smallpox.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Tdap / Td** ACIP Vaccine Recommendations. Last updated 2020 Jan [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/dtap.html>] accessed 04/21/2023.

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Varicella** ACIP Vaccine Recommendations. Last reviewed 2014 Nov [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/varicella.html>] accessed 04/21/2023.

## Medical Policy: IMMUNIZATIONS

Policy Number: 2.01.42

Page: 10 of 10

\*Centers for Disease Control and Prevention (CDC). Advisory Committee for Immunization Practices (ACIP). **Zoster (Shingles)** ACIP Vaccine Recommendations. Last updated 2022 Jan [<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/shingles.html>] accessed 04/21/2023.

\*Demicheli V, et al. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst Rev* 2018 Feb 1;(2):CD001269.

\*Demicheli V, et al. Vaccines for preventing influenza in the elderly. *Cochrane Database Syst Rev* 2018 Feb 1;(2):CD004876.

\*Jefferson TO, et al. Vaccines for preventing influenza in healthy children. *Cochrane Database Syst Rev* 2018 Feb 1;(2):CD004879.

State of New York Department of Financial Services. Circular Letter No. 13. Coverage for preventive and primary care services. Statutory Reference: New York Insurance Law Sections 3216(i)(17), 3221(l)(8) and 4303(j). 2006 May 10. [[https://www.dfs.ny.gov/insurance/circltr/2006/cl06\\_13.htm](https://www.dfs.ny.gov/insurance/circltr/2006/cl06_13.htm)] accessed 04/21/2023.

State of New York Department of Financial Services. ISC § 3216, § 3221, §4303. [<http://public.leginfo.state.ny.us/lawssrch.cgi?NVLWO:>] ISC Insurance: accessed 04/21/2023.

\*U. S. Food and Drug Administration. Vaccines, Blood and Biologicals. Vaccines licensed for use in the United States. Last updated 2022 Jul. [<https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm>] accessed 04/21/2023.

\*Key Article

### **KEY WORDS**

Immunizations, vaccines, ACIP

### **CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS**

Based upon our review, Immunizations are not addressed in a National or Local Medicare coverage determination or policy. However, Immunizations are addressed in the **Medicare Benefit Policy Manual, Chapter 15 – Covered Medical and Other Health Services, Section 50.4.4.2**. Please refer to the following website for Medicare Members:

[<https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/bp102c15.pdf>] Accessed 04/21/2023.

**Medicare Part D Vaccines:** [<https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/Vaccines-Part-D-Factsheet-ICN908764.pdf>] Dated 12/2022. Accessed 04/21/2023.